Picard Medical’s SynCardia to Reveal Emperor Heart In Vitro/In Vivo Data at Barcelona Summit
SynCardia will present first in vitro and in vivo data on its fully implantable Emperor artificial heart at a Barcelona summit Feb 15–18. The Feb 16 presentation by VP Clinical Affairs Dr. Andre Simon will outline device performance and surgical feasibility, informing regulatory and clinical adoption.
1. Presentation at European Mechanical Circulatory Support Summit
Picard Medical’s SynCardia Systems LLC will participate in the 19th European Mechanical Circulatory Support Summit & 11th International Course on Mechanical Circulatory Support and New Technologies in Advanced Heart Failure, held February 15–18 in Barcelona, Spain. The company’s VP of Clinical Affairs, Dr. Andre Simon, will deliver a dedicated session on February 16.
2. First In Vitro and In Vivo Data for Emperor TAH
The presentation titled “The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart” will showcase preclinical testing results. Details include device performance under simulated physiological conditions, durability metrics, and early surgical feasibility findings.
3. Potential Impact on Regulatory and Clinical Adoption
These pioneering data could inform upcoming regulatory submissions by demonstrating safety and functionality benchmarks. Clinical teams and industry stakeholders will assess the findings for potential integration into human trials and broader adoption in end-stage heart failure treatment.